Shannon Glueck, PharmDA

Acting Branch Chief

Branch 4

Division of Compounding II

Office of Compounding Quality and Compliance

Office of Compliance

Center for Drug Evaluation and Research

cc: United States Senate Committee on Health, Education, Labor and Pensions and Dr. Chaudhry.

The purpose of this letter is to inform you that both the medical community and the general public understand that your letter dated 12/13/2021 to the Federation of State Medical Boards is both misleading and dangerous, as it will lead to a continuation of harmful medical practices and the denial of early, aggressive treatments that have been shown to reduce morbidity and mortality associated with disease that results from the infection by the SARS-CoV-2 virus.

The public finds your letter to be misguided and spurious, to the point of nearly appearing erratic.

Please continue reading, signing, and sharing on Source: An Open Letter to the FDA on Ivermectin and COVID-19 Treatments